ERBB2 and breast carcinoma: EphA2 is also overexpressed and associated with poor prognosis in breast cancer, where it amplifies oncogenic signalling of the RTK erbB2 (HER2), and the loss of EphA2 in the mammary epithelium of mice slowed down tumour development and metastasis [46].